SEC Form 4 · accession 0001437749-18-002791

Oxford Immunotec Global PLC · OXFD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Feb 15, 2018

Accepted (ET)

Feb 16, 2018 · 4:30 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001586049

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Shares	Feb 15, 2018	M	500	$0.09	A	15,500	D
Ordinary Shares	Feb 15, 2018	S	500	$12.00	D	15,000	D
Ordinary Shares	Feb 16, 2018	M	2,500	$0.09	A	17,500	D
Ordinary Shares^F2	Feb 16, 2018	S	2,500	$12.015	D	15,000	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3	$0.09	Feb 15, 2018	M	500	D	—	Mar 31, 2020	Ordinary Shares	500	7,150	D
Stock Option (Right to Buy)^F3	$0.09	Feb 16, 2018	M	2,500	D	—	Mar 31, 2020	Ordinary Shares	2,500	4,650	D

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017.
F2The price reported for the sales on February 16, 2018 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.165 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
F3Exercise from an option award granted February 18, 2010, which became fully vested on April 1, 2014.